Dfb Soria, LLC

Medigene Ag

Tolmar, Inc.

Fougera Pharmaceuticals Inc.

Altana Inc.

Robert Lathrop

Keith Johnson

Yunik Chang

Ulrich Moebius

Irene Gander-Meisterernst

Roland Franke

Regina Greger

Johanna Holldack

Meidong Yang

Holly Maulhardt

Erwin Böhm

David W Osborne

Erwin Bohm

Gordon J Dow

Frances Furr Kelly

Rukmini Rajagopalan

A hydrophobic topical skin composition is disclosed. The composition includes greater than 50% w/w of the composition of a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of a plurality of taxane nanoparticles, wherein the mean particle size (number) of the taxane nanoparticles is from 0.1 microns to 1.5 microns, and wherein the taxane nanoparticles are crystalline nanoparticles or a combination of amorphous and crystalline nanoparticles.

Delivery of drug nanoparticles and methods of use thereof

Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

The invention relates to a medicament containing a compound of general formula (I), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, particularly a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, R=independently, a straight or branched C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, in particular a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)m-O]H group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;R]&#x2014; group, where R=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

Medicament for the treatment of viral skin and tumour diseases

The present disclosure generally relates to pharmaceutical corticosteroid compositions, and methods of making the same.

Corticosteroid compositions

The invention relates to a medicament containing a compound of general formula (I), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, particularly a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, R=independently, a straight or branched C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, in particular a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)m-O]H group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;R]- group, where R=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

The invention relates to a medicament containing a compound of general formula (1), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkynyl group, preferably a C-Calkyl, alkylene or alkynyl group, particularly a C-Calkyl, alkylene or alkynyl group, most preferably a Calkyl group, R2=independently, a straight or branched C-Calkyl, alkylene or alkynyl group, preferably a C-Calkyl, alkylene or alkynyl group, in particular a C-Calkyl, alkylene or alkynyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)&#x2014;O]H group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;(R)]&#x2014; group, where R=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof. 

A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.

Growing community of inventors

Fort Collins, CO, United States of America

Robert Lathrop